ReviewActa pharmaceutica Sinica. B2026
Advanced oral drug delivery systems: Current challenges and emerging technologies.
Review in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Orally activatable membrane fusion-mitochondria hitchhiking on intestinal macrophages for targeted therapy of bacterial meningitis and neuroinflammation.Bioactive materials · 2027Article
- Chitosan-TPP modification of SNEDDS enhances mucin interaction, apparent epithelial transport, and oral exposure of ezetimibe.Drug delivery and translational research · 2026Article
- Breaking the Solubility-Permeability Tradeoff: Surfactant-Mediated Enhancement of Oral Etoposide Absorption.Biomolecules · 2026Article
- Development of a Sacha Inchi Oil-Based Nanoemulsion Containing Mangosteen Pericarp Extract and Its Antioxidant Activity.Pharmaceutics · 2026Article
- Editorial of special column of hot topic reviews in drug delivery (II).Acta pharmaceutica Sinica. B · 2026Article
- Ionic Liquid-Enabled Drug Delivery Systems: Benefits, Limitations, and Future Perspectives.Pharmaceutics · 2026Review
- Recent Advances in Oral Drug Delivery Systems for BCS III Drugs.Current issues in molecular biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral dosage is the most commonly used and preferred method of drug administration due to its several advantages, including non-invasiveness, patient adherence, and ease of use. However, oral bioavailability can be influenced by several factors, such as drug solubility and mucosal permeability in the gastrointestinal tract, sometimes leading to poor and/or inconsistent absorption. In particular, low aqueous solubility presents a significant challenge in achieving adequate oral bioavailability and therapeutic effectiveness for many pharmaceutical compounds. Attempts to overcome these limitations have focused on deeper understanding of the physicochemical, biochemical, and biological barriers that limit overall drug bioavailability. To ensure better and stable pharmacokinetic behavior of orally administered drugs, various formulation strategies have been developed to enhance solubility, dissolution rate, membrane permeability, and overall oral bioavailability. This review article explores recent advancements in formulation techniques aimed at improving the biopharmaceutical properties of orally administered drugs. The challenges and development aspects of oral dosage forms are also addressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.